Ardelyx, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Michael G. Raab
- Full Time Employees
- 489
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 400 Fifth Avenue Waltham MA United States 02451
- IPO Date
- Jun 18, 2014
- CIK
- 0001437402
- Website
- ardelyx.com
- Similar Companies
- Business
- Ardelyx, Inc. (ARDX) is a biopharmaceutical company focused on the discovery, development and commercialization of first-in-class medicines that address significant unmet medical needs in gastrointestinal and nephrology indications. The company offers two approved products in the United States: IBSRELA (tenapanor), a minimally absorbed small molecule sodium/hydrogen exchanger 3 (NHE3) inhibitor indicated for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults; and XPHOZAH (tenapanor), an NHE3 inhibitor for the reduction of serum phosphorus in adults with chronic kidney disease (CKD) on dialysis. Ardelyx maintains a pipeline including RDX013, a small molecule potassium secretagogue for hyperkalemia; RDX020, a small molecule for metabolic acidosis; and RDX10531, a next-generation NHE3 inhibitor in preclinical development with potential applications across multiple therapeutic areas. Founded in 2007 and headquartered in Waltham, Massachusetts, with additional facilities in Newark, California, and Milwaukee, Wisconsin, Ardelyx operates primarily in the U.S. market while pursuing international commercialization through strategic partnerships, including agreements with Kyowa Kirin, Fosun Pharma and Knight Therapeutics for tenapanor outside the United States. In recent developments, Ardelyx reported third-quarter 2025 net product sales of $78.2 million for IBSRELA, up 92% year-over-year, and raised full-year 2025 guidance to $270-$275 million; secured a commercial supply agreement with Catalent Pharma Solutions for IBSRELA extending through 2028; appointed Eric Foster as Chief Commercial Officer to oversee strategies for its products; presented real-world evidence on XPHOZAH demonstrating patient satisfaction and phosphate reduction at ASN Kidney Week in November 2025; and initiated preclinical development of RDX10531 to support an investigational new drug submission in 2026.
Company News
ROSEN, LEADING TRIAL ATTORNEYS, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
ROSEN, A TOP RANKED LAW FIRM, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
ARDX Investor Alert: Ardelyx, Inc. Securities Class Action Notice - Contact Levi & Korsinsky
ARDX DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Ardelyx (ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026
Kaplan Fox Urges Ardelyx, Inc. (ARDX) Investors to Contact the Firm Before the Deadline on November 16, 2026
Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ARDX
Ardelyx, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - ARDX
ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Ardelyx, Inc. of Class Action Lawsuit and Upcoming Deadlines – ARDX
ARDX Deadline Alert: SueWallSt Reminds Ardelyx, Inc. (ARDX) Investors of Securities Class Action Deadline on November 16, 2026
ARDX CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds Ardelyx (ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026
Ardelyx to Report Third Quarter 2026 Financial Results on November 3, 2026
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit
ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Ardelyx, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ARDX
ARDX Investors Have Opportunity to Lead Ardelyx, Inc. Securities Fraud Lawsuit with SBS Law
Robbins LLP Urges ARDX Stockholders to Contact the Firm for Information About the Securities Class Action Against Ardelyx, Inc.
Bronstein, Gewirtz & Grossman LLC Urges Ardelyx, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
ARDX UPCOMING DEADLINE: Levi & Korsinsky Alerts Ardelyx, Inc. Stockholders of Securities Class Action - Contact the Firm
Kaplan Fox Reminds Investors of a Securities Class Action Against Ardelyx, Inc. (ARDX) - Deadline is November 16, 2026
ARDX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds Ardelyx (ARDX) Investors of Securities Class Action Lawsuit Deadline on November 16, 2026